Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study

Abstract

Poor prognosis is associated with patients with metastatic colorectal cancer. To seek effective methods, we examine the efficacy and safety of bevacizumab plus FOLFIRI as a second-line chemotherapy in Chinese patients with metastatic colorectal cancer (mCRC). A total of 55 patients with previous failure of oxaliplatin-based chemotherapy were included in this study, from October 2010 to February 2012. All patients received bevacizumab (5 mg/kg) plus FOLFIRI every other week until disease progression or intolerable toxicity occurred. The response rate was 31%, and the disease-controlled rate was 76.4%. The median progression-free survival was 6 months, and the median overall survival was 17 months. Adverse events (AEs) related to chemotherapy were mild to moderate. Only the incidence of grade 3-4 neutropenia reached to 25.5%. The incidence of AEs related to bevacizumab was low. These AEs included grade 3-4 toxicities of hypertension and proteinuria 5.4 and 3.6%, respectively. Bevacizumab plus FOLFIRI is an effective and safe regimen as a second-line treatment for patients with mCRC in China.

Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs

“…It inhibits the topoisomerase I, an enzyme which relaxes DNA supercoils formed during the processes of DNA replication and transcription, leading to breaks in DNA that result in DNA fragmentation [26]. It is a common component of combination chemotherapeutic regimens that are in clinical trials for its efficacy in certain cancers like small cell lung cancer, colorectal cancer and pancreatic cancer [27][28][29]. There is little information as to how irinotecan is taken up into the cell.…”

Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds

“…Gemcitabine and paclitaxel are used in the treatment of pancreatic cancer [17,18]. Irinotecan and 5-fluoro uracil have been used in a combination regimen for the treatment of colorectal and pancreatic cancers [19,20].…”

Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer

“…However, serious adverse reactions including hypertension, proteinuria, fatigue, and anorexia nervosa have limited its clinical application. 34,35 Therefore, it is urgent to reduce the toxic side effects and enhance therapeutic efficacy for the treatment of metastatic colorectal cancer.…”